Project description DEENESFRITPL Optimisation of the personalised medicine approach in ovarian cancer treatment Personalised medicine (PM) is a novel form of medical care that customises treatment to the disease and the patient. The advantages of this approach are recognised, but its clinical applications are limited due to high complexity and costs. The EU-funded ITHACA project aims to develop a PM platform that involves innovative in-vitro techniques, an advanced computational simulator and standard clinical data for the efficient screening of ovarian cancer therapies and the optimisation of the treatment for each patient. This approach will be validated using standard and primary cell lines to determine the patient-specific therapy outcome in women with ovarian cancer. The results of the project will provide the scientific community with invaluable tools for the further application of PM in the clinic. Show the project objective Hide the project objective Objective Personalised medicine (PM) is a novel approach to medical care that customises each treatment not just to the disease but also to the patient. While the advantages of this framework are widely recognised and its development is acknowledged as a fundamental societal challenge by the H2020 program, clinical applications are still limited, due to the increased complexity and costs, with respect to the current standard of care. ITHACA aims at developing an innovative PM toolkit that, relying on an advanced computational simulator, innovative in-vitro techniques and standard clinical data could provide an efficient and ethical framework for the screening of different ovarian cancer therapies and the identification of the most effective for each subject. This project builds on my experience with computational modelling and multidisciplinary research environments, to develop a programmable in-silico simulator capable of reproducing the patient-specific response to standard and novel ovarian cancer treatments. This tool will be extensively validated with both standard and primary cell lines and will then be used to determine patient-specific therapy outcome (RECIST 1.1 criteria) in women affected by ovarian cancer. Additionally it will be integrated in a novel bioreactor system for the in-vitro study of metastasization in HGSC. This compound device will allow for automatic treatment optimisation within an accurate and unique experimental model for this disease, and will thus provide an effective platform for personalised treatments development. Funding of this action will be a fundamental opportunity of career development, that will support my training in a highly innovative, interdisciplinary field while fostering the achievement of professional independence. Additionally the results of ITHACA will lead to high profile, impactful publications and provide the scientific community with enabling tools for the extensive application of PM in the clinic. Fields of science engineering and technologyenvironmental biotechnologybioremediationbioreactorsmedical and health sciencesclinical medicineoncologymedical and health scienceshealth sciencespersonalized medicine Keywords Mathematical model of cancer Therapy outcome prediction 3D cell culture Translational cancer research Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2019 - Individual Fellowships Call for proposal H2020-MSCA-IF-2019 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA Net EU contribution € 257 209,92 Address VIA ZAMBONI 33 40126 Bologna Italy See on map Region Nord-Est Emilia-Romagna Bologna Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 257 209,92 Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Partner Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement. UNIVERSITY OF NEW SOUTH WALES Australia Net EU contribution € 0,00 Address ANZAC PARADE 2052 Sydney See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 171 473,28
